HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

crotedumab

a glucagon receptor inhibitor in clinical trials (2015)

Also Known As:

REGN-1193; REGN1193

Networked: 1 relevant articles (0 outcomes, 0 trials/studies)

Bio-Agent Context: Research Results

Experts

1.	Aglione, JohnPaul: 1 article (08/2015)
2.	Cavino, Katie: 1 article (08/2015)
3.	Gromada, Jesper: 1 article (08/2015)
4.	Harp, Joyce: 1 article (08/2015)
5.	Kim, Jee Hae: 1 article (08/2015)
6.	Kim, Jinrang: 1 article (08/2015)
7.	Lee, Joseph: 1 article (08/2015)
8.	Murphy, Andrew J: 1 article (08/2015)
9.	Na, Erqian: 1 article (08/2015)
10.	Okamoto, Haruka: 1 article (08/2015)

Related Diseases

1.	Hypoglycemia (Reactive Hypoglycemia) 08/01/2015 - "Finally, administration of REGN1193 for 8 weeks to normoglycemic cynomolgus monkeys did not cause hypoglycemia or increase pancreatic α-cell area. " 08/01/2015 - "In summary, the GCGR-blocking antibody REGN1193 normalizes blood glucose in diabetic mice and monkeys but does not produce hypoglycemia in normoglycemic monkeys. "
2.	Hyperplasia 08/01/2015 - "Hyperglucagonemia and α-cell hyperplasia was observed in fibroblast growth factor 21-deficient mice treated with REGN1193. "
3.	Diabetes Mellitus 08/01/2015 - "Thus, REGN1193 provides a potential therapeutic modality for diabetes mellitus and acute hyperglycemic conditions. "
4.	Body Weight (Weight, Body) 08/01/2015 - "In diet-induced obese mice, REGN1193 reduced food intake, adipose tissue mass, and body weight. "

Related Drugs and Biologics

1.	Fibroblast Growth Factors (Fibroblast Growth Factor)
2.	Blood Glucose (Blood Sugar)